中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2013年
2期
166-169
,共4页
王妍%刘天舒%庄荣源%崔越宏%王志明%余一祎%侯君%孙益红%沈坤堂
王妍%劉天舒%莊榮源%崔越宏%王誌明%餘一祎%侯君%孫益紅%瀋坤堂
왕연%류천서%장영원%최월굉%왕지명%여일의%후군%손익홍%침곤당
胃肿瘤,进展期%新辅助化疗%根治性手术%治疗效果
胃腫瘤,進展期%新輔助化療%根治性手術%治療效果
위종류,진전기%신보조화료%근치성수술%치료효과
Stomach neoplasms,advanced%Neoadjuvant chemotherapy%Curative operation%Treatment outcomes
目的 探讨局部进展期胃癌术前化疗的疗效及安全性,以及影响术前化疗胃癌患者复发死亡的因素.方法 回顾性分析2007年7月至2011年6月间复旦大学附属中山医院肿瘤内科收治的49例局部进展期胃癌患者的临床资料.采用Cox比例风险模型来分析新辅助化疗患者复发死亡的危险因素.结果 其中48例患者化疗后在术前接受了影像学评估,术前化疗的有效率和疾病控制率分别为33.3%(16/48)和93.8%(45/48);另有1例因在化疗期间胃穿孔行急诊手术而未接受影像学评估.治疗后89.8%(44/49)的患者获得根治手术,其中90.9%的患者(40/44)接受了D2淋巴结清扫术.术后淋巴结转阴率为30.6%(15/49);术后病理有反应32例,其中2例获得完全病理缓解.术前化疗期间血液学毒性反应主要为白细胞下降,非血液学毒性反应主要为恶心呕吐,以1~2级为主.49例患者平均住院时间为11.6 d,其中2例(4.1%)分别因术后胰漏和胰周渗液而延长了住院时间.49例患者均接受了术后随访,中位随访时间为21.6个月,中位无复发生存期为29.6个月(95%CI:24.0~35.2),中位总生存期为34.6个月(95%CI:29.8~39.4).多因素预后分析显示,影像学疗效(P.=0.038,RR=0.168,95%CI:0.031~0.904)和病理反应(P=0.007,RR=0.203,95%CI:0.064~0.642)是影响本组患者术后复发死亡的独立因素.结论 术前化疗对于局部进展期胃癌具有较高的疾病控制率和R0切除率;影像学疗效和病理反应是影响局部进展期胃癌术前化疗患者最重要的预后指标.
目的 探討跼部進展期胃癌術前化療的療效及安全性,以及影響術前化療胃癌患者複髮死亡的因素.方法 迴顧性分析2007年7月至2011年6月間複旦大學附屬中山醫院腫瘤內科收治的49例跼部進展期胃癌患者的臨床資料.採用Cox比例風險模型來分析新輔助化療患者複髮死亡的危險因素.結果 其中48例患者化療後在術前接受瞭影像學評估,術前化療的有效率和疾病控製率分彆為33.3%(16/48)和93.8%(45/48);另有1例因在化療期間胃穿孔行急診手術而未接受影像學評估.治療後89.8%(44/49)的患者穫得根治手術,其中90.9%的患者(40/44)接受瞭D2淋巴結清掃術.術後淋巴結轉陰率為30.6%(15/49);術後病理有反應32例,其中2例穫得完全病理緩解.術前化療期間血液學毒性反應主要為白細胞下降,非血液學毒性反應主要為噁心嘔吐,以1~2級為主.49例患者平均住院時間為11.6 d,其中2例(4.1%)分彆因術後胰漏和胰週滲液而延長瞭住院時間.49例患者均接受瞭術後隨訪,中位隨訪時間為21.6箇月,中位無複髮生存期為29.6箇月(95%CI:24.0~35.2),中位總生存期為34.6箇月(95%CI:29.8~39.4).多因素預後分析顯示,影像學療效(P.=0.038,RR=0.168,95%CI:0.031~0.904)和病理反應(P=0.007,RR=0.203,95%CI:0.064~0.642)是影響本組患者術後複髮死亡的獨立因素.結論 術前化療對于跼部進展期胃癌具有較高的疾病控製率和R0切除率;影像學療效和病理反應是影響跼部進展期胃癌術前化療患者最重要的預後指標.
목적 탐토국부진전기위암술전화료적료효급안전성,이급영향술전화료위암환자복발사망적인소.방법 회고성분석2007년7월지2011년6월간복단대학부속중산의원종류내과수치적49례국부진전기위암환자적림상자료.채용Cox비례풍험모형래분석신보조화료환자복발사망적위험인소.결과 기중48례환자화료후재술전접수료영상학평고,술전화료적유효솔화질병공제솔분별위33.3%(16/48)화93.8%(45/48);령유1례인재화료기간위천공행급진수술이미접수영상학평고.치료후89.8%(44/49)적환자획득근치수술,기중90.9%적환자(40/44)접수료D2림파결청소술.술후림파결전음솔위30.6%(15/49);술후병리유반응32례,기중2례획득완전병리완해.술전화료기간혈액학독성반응주요위백세포하강,비혈액학독성반응주요위악심구토,이1~2급위주.49례환자평균주원시간위11.6 d,기중2례(4.1%)분별인술후이루화이주삼액이연장료주원시간.49례환자균접수료술후수방,중위수방시간위21.6개월,중위무복발생존기위29.6개월(95%CI:24.0~35.2),중위총생존기위34.6개월(95%CI:29.8~39.4).다인소예후분석현시,영상학료효(P.=0.038,RR=0.168,95%CI:0.031~0.904)화병리반응(P=0.007,RR=0.203,95%CI:0.064~0.642)시영향본조환자술후복발사망적독립인소.결론 술전화료대우국부진전기위암구유교고적질병공제솔화R0절제솔;영상학료효화병리반응시영향국부진전기위암술전화료환자최중요적예후지표.
Objective To evaluate the efficacy and safety of neoadjuvant chemotherapy in patients with locally advanced gastric cancer,and to analyze the relevant factors of recurrent death of gastric cancer after adjuvant chemotherapy.Methods Clinical data of 49 patients who underwent neoadjuvant chemotherapy for locally advanced gastric cancer between July 2007 and June 2011 were reviewed.Preoperative staging was determined by endoscopic ultrasonography and abdominal computer tomography(CT) or magnetic resonance imaging(MRI).Chemotherapy was administered for regimen of two or three drugs.Prognostic factors were analyzed by univariate and multivariate analysis with Cox proportional hazard model.Results The response rate was 33.3%(16/48) and disease control rate was 93.8 % (45/48).Forty-four (89.8 %,44/49) patients received curative resection after neoadjuvant chemotherapy,among whom 90.9% (40/44) underwent D2 lymphadenctomy.Thirty-two cases had pathological response and 2 patients had pathological complete response.The average hospital stay was 11.6 days and 2 patients had longer hospitalization because of postoperative pancreatic complications.The toxicities were most in grade 1-2.All the patients were followed up postoperatively and the median follow-up was 21.6 months.Median progression-free survival was 29.6(95%CI:24.0-35.2) months and median overall survival was 34.6 months (95%CI:29.8-39.4).Imaging response(P=0.038,RR=0.168,95%CI:0.031-0.904) and pathological response (P=0.007,RR=0.203,95%CI:0.064-0.642) were identified as independent prognostic factors with COX multivariate analysis.Conclusions Neoadjuvant chemotherapy has quite high disease control rate and R0 resecting rate for patients with locally advanced gastric cancer.Imaging response and pathological response are most important prognostic factors in those patients.